FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes: a randomised controlled trial
Phase of Trial: Phase III
Latest Information Update: 17 Sep 2018
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms FLAIR
- 29 Jun 2017 Planned End Date changed from 20 Aug 2018 to 1 Jan 2030.
- 04 Nov 2015 Accrual to date is 27% according to United Kingdom Clinical Research Network.
- 05 Oct 2015 Accrual to date is 25% according to the United Kingdom Clinical Research Network record.